Related Experiment Video
Updated: Jul 31, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Ranolazine Toxicity Secondary to Paxlovid
Bradley Casey1, Robert C Vernick1, Amol Bahekar2
1Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, USA.
Paxlovid, an antiviral for COVID-19, can cause dangerous drug interactions. A patient experienced toxicity from ranolazine after taking Paxlovid, highlighting the need for careful medication management.
Area of Science:
- Pharmacology
- Infectious Diseases
- Internal Medicine
Background:
- The FDA issued an Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir/ritonavir) in December 2021 for high-risk pediatric patients (12+ years) with mild to moderate COVID-19.
- Paxlovid is known to have numerous drug-to-drug interactions due to its impact on liver metabolism.
- Ranolazine is a medication with a narrow therapeutic index, making it susceptible to toxicity from drug interactions.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents